Moreadith Randall reported grant involving 85,558 derivative units of Serina Therapeutics, Inc. at $0.00 for $0 on May 21, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Scientific Officer
Chief Scientific Officer
Filed May 26, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
85,558Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
85,558Direct
Trade date
May 21, 2026Grant
Filed
May 26, 2026, 7:33 PM ET5-day reporting delay
Accession
0001301120-26-000021Code A · Transaction 385625
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

SER price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SER · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +6.3%1w ago −10%1d ago −11%
Returns since7d −8.3%30d −5.2%90d +37%180d1y

Footnotes in full

F1: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.